SCHEMBL3375875

SCHEMBL3375875

Brc1ccnc2[nH]ncc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.52
AXL P30530 2/20 0.47
NOS1 P29475 2/20 0.47
PIK3CD O00329 1/20 0.46
PIK3CA P42336 1/20 0.46
PIK3CB P42338 1/20 0.46
NUDT1 P36639 3/20 0.45
XDH P47989 2/20 0.44
RET P07949 1/20 0.44
PI4KA P42356 1/20 0.44
LRRK2 Q5S007 1/20 0.44
PI4K2B Q8TCG2 1/20 0.44
PI4K2A Q9BTU6 1/20 0.44
PI4KB Q9UBF8 1/20 0.44
MAPK1 P28482 2/20 0.44
MKNK1 Q9BUB5 1/20 0.44
BRD4 O60885 1/20 0.43
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
ADORA2A P29274 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29705496 0.75 NUDT1 (0.53) PRKCIAXLNOS1PIK3CDPIK3CA
SCHEMBL29506132 0.75 NOS1 (0.47) NOS1PIK3CDPIK3CAPIK3CBNUDT1
SCHEMBL290117 0.75 NOS1 (0.47) NOS1PIK3CDPIK3CAPIK3CBNUDT1
SCHEMBL2112472 0.75 PIK3CD (0.46) PIK3CDPIK3CAPIK3CBNUDT1XDH
SCHEMBL29487195 0.75 XDH (0.53) PIK3CDPIK3CAPIK3CBNUDT1XDH
SCHEMBL9933985 0.75 NUDT1 (0.49) PIK3CDPIK3CAPIK3CBNUDT1XDH
SCHEMBL2619223 0.75 CHEK1 (0.47) PIK3CDPIK3CAPIK3CBNUDT1XDH
SCHEMBL11506 0.75 NUDT1 (0.53) PRKCIAXLNOS1PIK3CDPIK3CA
SCHEMBL21855766 0.75 PIK3CD (0.46) PIK3CDPIK3CAPIK3CBNUDT1XDH
SCHEMBL1835481 0.75 XDH (0.53) PIK3CDPIK3CAPIK3CBNUDT1XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118146219-A Preparation process of 1H-pyrazolo [3,4-b ] pyridine-4-amine intermediate 南京艾康生物科技有限公司 2024-06-07 CN claimed
CN-117050075-B Biaryl ring BET inhibitor and synthetic method and application thereof CHINA PHARMACEUTICAL UNIVERSITY (CN) 2026-05-26 CN disclosed
CN-122070277-A Androgen receptor PROTAC 葛兰素史密斯克莱知识产权发展有限公司 2026-05-19 CN disclosed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
US-12577231-B2 Androgen receptor PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-03-17 US disclosed
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 US disclosed
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-01 US disclosed
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 EP disclosed
EP-3129372-A1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C Cancer Research Technology Limited (GB) 2017-02-15 EP disclosed
US-20170002016-A1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2017-01-05 US disclosed
US-20170002016-A1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2017-01-05 US disclosed
US-20160137652-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2016-05-19 US disclosed
WO-2015148597-A1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C IGNYTA, INC. (US) 2015-10-01 WO disclosed
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C WINDTREE THERAPEUTICS, INC. 2015-10-01 US disclosed
WO-2015148597-A1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C IGNYTA, INC. (US) 2015-10-01 WO disclosed
WO-2014052699-A9 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C IGNYTA, INC. (US) 2015-07-16 WO disclosed
WO-2014052699-A9 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C IGNYTA, INC. (US) 2015-07-16 WO disclosed
EP-2239262-A2 Fused ring heterocycle kinase modulators SGX Pharmaceuticals, Inc. (US) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170002016-A1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM5 PRKCI 1597/4885AXL 1566/4885NOS1 3201/4885
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP PRKCI 2356/4885AXL 1389/4885NOS1 2929/4885
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 PRKCI 333/4885AXL 4415/4885NOS1 2727/4885
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS AR, CRBN, PSMA3 PRKCI 2104/4885AXL 2754/4885NOS1 4845/4885
US-20160137652-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT PRKCI 2883/4885AXL 4634/4885NOS1 146/4885
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C PRKCQ, PRKCA, PRKCZ PRKCI 7/4885AXL 4270/4885NOS1 3314/4885
US-12577231-B2 Androgen receptor PROTACS AR, CRBN, PSMA3 PRKCI 2104/4885AXL 2754/4885NOS1 4845/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD PRKCI 1115/4885AXL 2359/4885NOS1 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.